Every card below shows the score and the exact filing data it was computed from — no unexplained numbers. Some signals (P-02, P-03, P-08, P-09, P-10, P-11) pull live documents from SEC EDGAR the first time you view this company; a few of those (P-03, P-10, P-11) use AI to read the filing text, but every AI claim must quote the actual document verbatim or it's discarded — never a guess.
Ask follow-up questions about the latest 10-K, with citations verified against the actual text. No account needed.
Run the bounded investigation agent — reads this company's signals and writes a short, cited summary.
{
"icr_by_year": {
"2025-12-31": -991.901,
"2024-12-31": -333.484,
"2023-12-31": -513.496,
"2022-12-31": -1005.558
},
"consecutive_years_below_1": 4,
"altman_z_double_prime": -1340.017,
"definitions": {
"zombie": "ICR<1 for 3+ consecutive FYs (BIS 2018)",
"z_distress": "<1.1 distress, 1.1-2.6 gray, >2.6 safe"
},
"inputs": {
"ebit_t": -5294765,
"interest_expense_t": 5338
},
"stale": false,
"latest_filing_period": "2025-12-31",
"source": {
"url": "https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/0001493152-26-012726-index.htm",
"form": "10-K",
"filed": "2026-03-26"
}
}{
"clusters": [
{
"event_8k": "2026-07-01",
"form4_count": 3,
"form4_dates": [
"2026-06-30"
]
}
],
"form4_total_1y": 44,
"events_8k_1y": 5,
"window_days": 14,
"note": "Timing pattern only — direction (buy/sell) requires parsing each Form 4 XML; treat as a read-the-filings triage flag, not an accusation."
}{
"sc13d_filings": [],
"ai_signals": [
{
"kind": "other",
"summary": "Pursuing co-development relationships with commercial pharmaceutical companies for PV-10",
"quote": "Our goals are to pursue drug approval pathways and/or co-development relationships with commercial pharmaceutical companies for ITU PV-10 based on these indications and data.",
"quote_verified": true
},
{
"kind": "other",
"summary": "Exploring co-development collaboration or out-license for systemic drug candidate",
"quote": "and/or pursue a co-development collaboration or out-license arrangement for this route of administration and disease area",
"quote_verified": true
},
{
"kind": "other",
"summary": "Exploring co-development collaboration or out-license for other disease areas",
"quote": "and/or pursue a co-development collaboration or out-license arrangement for the respective disease area and route of administration",
"quote_verified": true
},
{
"kind": "other",
"summary": "May relinquish product rights through licensing or other arrangements for funding",
"quote": "in the event that additional funds are obtained through licensing or other arrangements, these arrangements may require us to relinquish rights to some of our products, product candidates, and technologies",
"quote_verified": true
},
{
"kind": "other",
"summary": "Considering corporate collaborations as capital source",
"quote": "Management plans to access capital resources through possible public or private equity offerings, including the 2025 Financing, exchange offers, debt financings, corporate collaborations, or other means.",
"quote_verified": true
}
],
"quotes_discarded_unverified": 0,
"ai_status": "ok",
"method": "Deterministic 13D count + LLM language read (quote-verified)"
}{
"current": {
"filed": "2026-03-26",
"tokens": 30837,
"uncertainty_per_1k": 14.14,
"negative_per_1k": 5.87,
"litigious_per_1k": 2.24
},
"prior": {
"filed": "2025-03-28",
"tokens": 29933,
"uncertainty_per_1k": 14.57,
"negative_per_1k": 5.85,
"litigious_per_1k": 2.44
},
"ratios": {
"uncertainty": 0.971,
"negative": 1.004
},
"method": "Loughran-McDonald dictionary densities (lite subset unless full CSV present)"
}{
"exposures": [],
"ppe_share_of_assets": null,
"quotes_discarded_unverified": 0
}